Trial Profile
A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cediranib (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 17 Sep 2010 Planned end date changed from 1 Oct 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.